
Eli Lilly Crosses $20B in 2026 Acquisitions as AI Rewrites Pharma's Global Deal Logic
Eli Lilly has spent more than $20 billion acquiring biotech firms in 2026, a single-year record, as AI-driven drug discovery compresses timelines and raises the value of early-stage assets worldwide. Deals span oncology, rare disease, and vaccines — reflecting a global industry shift toward buying AI-native pipelines rather than building internally. The strategy mirrors moves by European and Asian pharma rivals, but at a scale that now defines the sector's acquisition benchmark.





























